Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 92

1.

Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.

Zhu H, Wang J, Yin J, Lu B, Yang Q, Wan Y, Jia C.

Cell Physiol Biochem. 2018;45(3):1121-1135. doi: 10.1159/000487353. Epub 2018 Feb 7.

2.

PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma.

Yang L, Wang YZ, Zhu HH, Chang Y, Li LD, Chen WM, Long LY, Zhang YH, Liu YR, Lu J, Qin YZ.

DNA Cell Biol. 2017 Dec;36(12):1099-1107. doi: 10.1089/dna.2017.3951. Epub 2017 Sep 27.

PMID:
28953414
3.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

4.

PRAME is critical for breast cancer growth and metastasis.

Sun Z, Wu Z, Zhang F, Guo Q, Li L, Li K, Chen H, Zhao J, Song D, Huang Q, Li L, Xiao J.

Gene. 2016 Dec 5;594(1):160-164. doi: 10.1016/j.gene.2016.09.016. Epub 2016 Sep 12.

PMID:
27632898
5.

The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas.

Nettersheim D, Arndt I, Sharma R, Riesenberg S, Jostes S, Schneider S, Hölzel M, Kristiansen G, Schorle H.

Br J Cancer. 2016 Aug 9;115(4):454-64. doi: 10.1038/bjc.2016.187. Epub 2016 Jul 21.

6.

Preferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis.

Huang Q, Wei H, Wu Z, Li L, Yao L, Sun Z, Li L, Lin Z, Xu W, Han S, Cao W, Xu Y, Song D, Yang X, Xiao J.

PLoS One. 2016 Jul 8;11(7):e0149640. doi: 10.1371/journal.pone.0149640. eCollection 2016.

7.

PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR.

Oncotarget. 2016 Jul 19;7(29):45352-45369. doi: 10.18632/oncotarget.9977.

8.

PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling.

Xu Y, Rong LJ, Meng SL, Hou FL, Zhang JH, Pan G.

Eur Rev Med Pharmacol Sci. 2016;20(6):1057-63.

9.

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW.

Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071.

10.

PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.

Xu Y, Yue Q, Wei H, Pan G.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14549-55. eCollection 2015.

11.

PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.

Chisholm KM, Rivetta CV, Heerema-McKenney A.

Ann Clin Lab Sci. 2015 Spring;45(2):121-7.

PMID:
25887863
12.

Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy.

Mitsuhashi K, Masuda A, Wang YH, Shiseki M, Motoji T.

Int J Hematol. 2014 Jul;100(1):88-95. doi: 10.1007/s12185-014-1593-z. Epub 2014 May 13.

PMID:
24820636
13.

PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.

Abdelmalak CA, Yahya RS, Elghannam DM, El-Khadragy AE, Abd El Messih HM.

Clin Lab. 2014;60(1):55-61.

PMID:
24600975
14.

Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?

Szczepanski MJ, Whiteside TL.

Biomark Med. 2013 Aug;7(4):575-8. doi: 10.2217/bmm.13.68. No abstract available.

15.

PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).

Bullinger L, Schlenk RF, Götz M, Botzenhardt U, Hofmann S, Russ AC, Babiak A, Zhang L, Schneider V, Döhner K, Schmitt M, Döhner H, Greiner J.

Clin Cancer Res. 2013 May 1;19(9):2562-71. doi: 10.1158/1078-0432.CCR-11-2524. Epub 2013 Feb 26.

16.

The cancer testis antigen PRAME as a biomarker for solid tumor cancer management.

Goodison S, Urquidi V.

Biomark Med. 2012 Oct;6(5):629-32. doi: 10.2217/bmm.12.65. Review. No abstract available.

PMID:
23075240
17.

Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.

Gutierrez-Cosío S, de la Rica L, Ballestar E, Santamaría C, Sánchez-Abarca LI, Caballero-Velazquez T, Blanco B, Calderón C, Herrero-Sánchez C, Carrancio S, Ciudad L, Cañizo C, San Miguel JF, Pérez-Simón JA.

Leuk Res. 2012 Jul;36(7):895-9. doi: 10.1016/j.leukres.2012.02.030. Epub 2012 Apr 13.

PMID:
22503131
18.

Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses.

Winkler C, Steingrube DS, Altermann W, Schlaf G, Max D, Kewitz S, Emmer A, Kornhuber M, Banning-Eichenseer U, Staege MS.

Cancer Immunol Immunother. 2012 Oct;61(10):1769-79. Epub 2012 Mar 15.

PMID:
22419371
19.

PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.

Brenne K, Nymoen DA, Reich R, Davidson B.

Am J Clin Pathol. 2012 Feb;137(2):240-7. doi: 10.1309/AJCPGA95KVSAUDMF.

PMID:
22261449
20.

Insights on PRAME and osteosarcoma by means of gene expression profiling.

Toledo SR, Zago MA, Oliveira ID, Proto-Siqueira R, Okamoto OK, Severino P, Vêncio RZ, Gamba FT, Silva WA, Moreira-Filho CA, Torre CA, Alves MT, Garcia-Filho RJ, Simpson AJ, Petrilli AS.

J Orthop Sci. 2011 Jul;16(4):458-66. doi: 10.1007/s00776-011-0106-7. Epub 2011 Jun 21.

PMID:
21691740

Supplemental Content

Support Center